Riskpilot← Back to searchSign inGet full accessJazz Pharmaceuticals Denmark ApS
APSActiveCVR 39791447Kampmannsgade 2Wholesale of pharmaceutical and medical goods · NACE 4646Est. 201812 employeeswww.jazzpharma.com
Revenue 2024
DKK 36,7M
+15% vs 2023
EBITDA margin
6.4%
+5% vs 2023
Equity ratio
37.9%
Financial strength
Net profit 2024
DKK 1,5M
+158% vs 2023
| Revenue | DKK 36,7M | +15% |
| EBITDA | DKK 2,4M | +5% |
| Net profit | DKK 1,5M | +158% |
| Total assets | DKK 32,5M | -10% |
| Equity | DKK 12,3M | +14% |
| Employees | 12 | — |
Legal name
Jazz Pharmaceuticals Denmark ApS
CVR number
39791447
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17. august 2018
Share capital
DKK 50.000
Employees
12 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at markedsføre, distribuere og sælge produkter og tjenesteydelser samt al virksomhed, som efter direktionens skøn har forbindelse hermed.
Address
Kampmannsgade 2
Email
nordicinfo@jazzpharma.com
Website
www.jazzpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 16.469 | 21.714 | 30.364 | 31.788 | 36.709 |
| Staff expenses | -14.302 | -20.845 | -26.977 | -29.546 | -34.350 |
| EBITDA | 2.168 | 869 | 3.388 | 2.242 | 2.359 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 2.168 | 869 | 3.388 | 2.242 | 2.359 |
| Net financials | -333 | -441 | -1.409 | -626 | -358 |
| Profit before tax | 1.835 | 428 | 1.979 | 1.616 | 2.001 |
| Tax | 294 | -133 | 6 | 1.021 | 462 |
| Net profit | 1.541 | 560 | 1.973 | 595 | 1.538 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 19.286 | 21.014 | 27.479 | 36.081 | 32.452 |
| Equity | 7.629 | 8.189 | 10.162 | 10.757 | 12.295 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 11.657 | 12.825 | 17.317 | 25.325 | 20.157 |
| Total debt | 11.657 | 12.825 | 17.317 | 25.325 | 20.157 |
EBITDA margin
6.4%
This company
15.8%
Market median
-59% vs market
20202024
Equity ratio
37.9%
This company
38.2%
Market median
+1% vs market
20202024
Return on equity
12.5%
This company
18.4%
Market median
+32% vs market
20202024
Net profit margin
4.2%
This company
8.1%
Market median
-48% vs market
20202024
Asset turnover
1.13×
This company
1.12×
Market median
+1% vs market
20202024
Debt / equity
1.64×
This company
0.62×
Market median
-165% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
KE Management | Management | 2022 |
DJ Management | Management | 2025 |
JP | Founder | 2018 |
| Former (2) | ||
SJ Management | Management | 2021 – 2025 |
JD Management | Management | 2018 – 2021 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2021 | |
| Individual | 100% | 100% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Jazz Pharmaceuticals Denmark ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kamilla Enggaard Have | Management | 0 companies |
| David James Spackman | Management | 0 companies |
| Samantha Jane Laura Pearce | Management | 0 companies |
| Joseph Dagher | Management | 0 companies |
| Jazz Pharmaceuticals Ireland Limited | Founder | 0 companies |